These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30584321)

  • 1. Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
    Liu J; Zhong Y; Peng S; Zhou X; Gan X
    Onco Targets Ther; 2018; 11():8623-8632. PubMed ID: 30584321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
    Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
    Front Oncol; 2022; 12():732814. PubMed ID: 35280727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.
    Zhou GW; Xiong Y; Chen S; Xia F; Li Q; Hu J
    Medicine (Baltimore); 2016 Aug; 95(35):e4611. PubMed ID: 27583876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis.
    Zhou C; Li M; Wang Z; An D; Li B
    Int Immunopharmacol; 2022 Jan; 102():108353. PubMed ID: 34883352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
    Addeo A; Banna GL; Metro G; Di Maio M
    Front Oncol; 2019; 9():264. PubMed ID: 31058078
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
    Xian F; Wu J; Zhong L; Xu G
    Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xian F; Wu J; Yuan YL; Bie J; Xu GH
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(4):1494-1502. PubMed ID: 36876689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
    Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
    Tan Q; Dai L; Wang Y; Liu S; Liang T; Luo R; Wang S; Lou N; Chen H; Zhou Y; Zhong Q; Yang J; Xing P; Hu X; Liu Y; Zhou S; Yao J; Wu D; Zhang Z; Tang L; Yu X; Han X; Shi Y
    Cancer Immunol Immunother; 2022 Jul; 71(7):1681-1691. PubMed ID: 34817638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
    Wu FZ; Song JJ; Zhao ZW; Huang XF; Mao JT; Tu JF; Chen MJ; Chen WQ; Fang SJ; Zheng LY; Fan XX
    Math Biosci Eng; 2019 Aug; 16(6):7921-7933. PubMed ID: 31698647
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer.
    Ru CH; Zhuang YB
    Comb Chem High Throughput Screen; 2018; 21(10):711-717. PubMed ID: 30686251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.
    Chang CH; Shih AC; Chang YH; Chen HY; Chao YT; Hsu YC
    Front Oncol; 2021; 11():759497. PubMed ID: 34868974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis.
    Yang Y; Pang Z; Ding N; Dong W; Ma W; Li Y; Du J; Liu Q
    Oncotarget; 2016 Nov; 7(45):74350-74361. PubMed ID: 27542277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
    An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
    Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Xu Z; Yi F; Yu D; Xu J; Wei Y; Zhang W
    Cancer Med; 2019 Feb; 8(2):629-642. PubMed ID: 30628185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.